plozalizumab   Click here for help

GtoPdb Ligand ID: 8921

Synonyms: hu1D9 | MLN-1202 | MLN1202
Immunopharmacology Ligand
Compound class: Antibody
Comment: Plozalizumab is a humanised anti-CCR2 monoclonal antibody, being investigated for its anti-inflammatory actions [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide analysis using the heavy and light chain variable amino acid sequences submitted with the INN record for plozalizumab, identifies 100% matches with sequences from patent US6696550 B2 [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Plozalizumab (research code MLN-1202) progressed to Phase 2 clinical trial for its potential immunomodulatory effect in atherosclerotic cardiovascular disease, diabetic nephropathy and multiple sclerosis. There is no evidence of continuing development of the antibody.
Patent US6663863 B2 describes the possible use of this antibody to prevent stenosis and restenosis by reducing the inflammatory and fibro-proliferative processes which underlie atherosclerotic plaque formation or restenosis resulting from vascular injury during revascularization procedures [1].